OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Samsung Forecasts Strong Q4 Profit on AI-Driven Memory Chip Boom 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
SAN FRANCISCO, March 17, 2017 -- Hagens Berman Sobol Shapiro LLP reminds investors in Stemline Therapeutics, Inc. (NASDAQ:STML) of the April 4, 2017 Lead Plaintiff deadline in the pending securities class action.
If you purchased or otherwise acquired securities of Stemline (1) pursuant to Stemline’s secondary public offering on or about January 20, 2017 or (2) on the open market between January 6, 2017 and February 1, 2017 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more information visit:
https://www.hbsslaw.com/cases/STML
or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected].
On February 2, 2017, TheStreet published an article entitled “Side Effect Kills Cancer Patient in Stemline Therapeutics Drug Trial, the Company Raises Money.” TheStreet reported that investors who bought into a $45 million Stemline Therapeutics stock offering on January 19, 2017 were not told that one day prior to the financing, a cancer patient in a clinical trial died from a severe side effect, a type of low blood pressure, tied to the Company’s SL-401 drug.
This news drove the price of Stemline shares down over 42% on February 2, 2017.
“A cancer patient’s death occurring from Stemline SL-401 related side effects is a tragic event and is a fact reasonable investors would want to know about,” said Hagens Berman partner Reed Kathrein.
Whistleblowers: Persons with non-public information regarding Stemline should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact: Reed Kathrein, 510-725-3000
